AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

RecruitingEARLY Phase 1Ages 18 Years - 51 YearsFemaleWolfson Medical Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more). The main questions it aims to answer are: * Does topical TXA shorten uterine closure time? * Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes. Participants will: * Be randomly assigned to receive either topical TXA or placebo during cesarean delivery. * Have standard surgery and postoperative care identical in both groups. * Provide routine clinical data, including hemoglobin levels and

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Women aged 18 to 51 years * Singleton pregnancy * Elective cesarean delivery scheduled at โ‰ฅ37+0 weeks of gestation * First or second cesarean delivery only * Low transverse uterine incision planned * Double-layer uterine closure using 1-0 Vicryl sutures * Ability to provide written informed consent Exclusion Criteria: * Known allergy or hypersensitivity to tranexamic acid (TXA) * History of bleeding or coagulation disorders * Previous postpartum hemorrhage * Placenta previa or placenta accreta spectrum * Presence of uterine myomas * Current use of anticoagulant or antiplatelet medications * Planned or intraoperative conversion to general anesthesia * Known uterine malformations * Known bleeding tendency or thromboembolic disease
๐Ÿ’Š

What it tests

  • Tranexamic Acid (Topical)
  • Normal Saline (Placebo)
๐Ÿ“

Where

4 sites
Edith Wolfson Medical Center
Holon, Israel
Meir medical center
Kfar Saba, Israel
Rabin medical center
Petah Tikva, Israel
Kaplan medical center
Rehovot, Israel
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy